Search results (986)
« Back to PublicationsCongenital myasthenic syndrome: is it time for a name change to genetic myasthenic syndrome?
Journal article
Ramdas S. et al, (2026), Brain, 149, 1816 - 1818
Identification of genetic risk loci associated with aquaporin 4-positive neuromyelitis optica spectrum disorder: a genome-wide association study
Journal article
Attfield KE. et al, (2026), The Lancet Neurology, 25, 482 - 491
Structure–function multilayer network integration and cognition in multiple sclerosis
Journal article
Breedt LC. et al, (2026), Network Neuroscience, 10, 400 - 417
Myelin oligodendrocyte glycoprotein antibody-associated disease and relapse risk: Effects of smoking and vascular risk factors
Conference paper
Yeh WZ. et al, (2026), Multiple Sclerosis Journal
Myelin oligodendrocyte glycoprotein antibody-associated disease and relapse risk: Effects of smoking and vascular risk factors.
Journal article
Yeh WZ. et al, (2026), Mult Scler
Prediction of relapse in myelin oligodendrocyte glycoprotein antibody-associated disease: external validation of the MOG-AR score
Journal article
Yeh WZ. et al, (2026), Journal of Neurology, 273
Myasthenic syndromes: mistaking genetic for acquired
Journal article
Henehan L. et al, (2026), Practical Neurology, 26, 164 - 168
Brain Age Estimation on T2 ‐ FLAIR Scans for Application to Multiple Sclerosis
Journal article
Colman J. et al, (2026), Human Brain Mapping, 47
Predictive factors for immunosuppression-associated severe and opportunistic infections in AQP4-IgG Neuromyelitis Optica Spectrum Disorder
Journal article
Greco G. et al, (2026), Multiple Sclerosis Journal, 32, 326 - 337
Lessons Learned: Quality Analysis of Optical Coherence Tomography in Neuromyelitis Optica
Journal article
Salih H. et al, (2026), Annals of Clinical and Translational Neurology, 13, 581 - 592
Serum GFAP and NfL augment a metabolomics-driven strategy for long-term prediction of multiple sclerosis progression
Journal article
Kacerova T. et al, (2026), Communications Medicine, 6
Optimal strategies for treatment discontinuation in MOG antibody-associated disease
Journal article
Yeh WZ. et al, (2026), Brain
EQ-5D-5L in Multiple Sclerosis: Estimated Utility Values, Minimal (Clinically) Important Changes, and Direct and Indirect Influences Over Time
Journal article
Young CA. et al, (2026), Value in Health, 29, 303 - 310
Vascular Comorbidities and an Increased Comorbidity Score Are Associated With Disability and Disability Progression in Secondary Progressive Multiple Sclerosis
Journal article
John NA. et al, (2026), European Journal of Neurology, 33